SCHEMBL338384

SCHEMBL338384

Nc1nc2[nH]c(=O)sc2c(=O)[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.52
MAPT P10636 2/20 0.46
DYRK1A Q13627 1/20 0.42
PNP P00491 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
PMP22 Q01453 1/20 0.41
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CDK2 P24941 1/20 0.37
THRB P10828 2/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
HBB P68871 1/20 0.36
HIF1A Q16665 1/20 0.36
QTRT1 Q9BXR0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8435570 0.81 RPS6KA3 (0.49) RPS6KA3MAPTDYRK1APNPKDM4E
SCHEMBL6975489 0.81 RPS6KA3 (0.49) RPS6KA3MAPTDYRK1APNPKDM4E
SCHEMBL22060804 0.69 RPS6KA3 (0.37) RPS6KA3
SCHEMBL17904270 0.69 RPS6KA3 (0.37) RPS6KA3MAPTKDM4EALDH1A1LMNA
SCHEMBL21895447 0.69 RPS6KA3 (0.37) RPS6KA3
Thiazolopyrimidine SCHEMBL1703410 0.68 RPS6KA3 (0.52) RPS6KA3MAPTPNPKDM4EALDH1A1
SCHEMBL3755970 0.68 RPS6KA3 (1.00) RPS6KA3MAPTPNPKDM4EALDH1A1
SCHEMBL8664276 0.68 PNP (0.32) RPS6KA3PNP
SCHEMBL842227 0.67 RPS6KA3 (0.70) RPS6KA3MAPTKDM4EALDH1A1HSD17B10
8-Aminoguanine SCHEMBL21760 0.66 KDM4E (0.60) MAPTDYRK1APNPKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3568400-B1 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-11-19 EP disclosed
EP-3568400-B1 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-11-19 EP disclosed
EP-3568400-C0 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-11-19 EP disclosed
WO-2025032082-A1 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2025-02-13 WO disclosed
WO-2025032082-A1 PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-THIAZOLO[4,5-D]PYRIMIDINE-2,7-DIONE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2025-02-13 WO disclosed
US-12152051-B2 Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application Shanghai De Novo Pharmatech Co., Ltd. (CN) 2024-11-26 US disclosed
EP-3695837-B1 A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR FOR TREATING HEPATITIS B HOFFMANN LA ROCHE (CH) 2024-11-20 EP disclosed
EP-3854799-B1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2024-07-17 EP disclosed
EP-3854799-B1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2024-07-17 EP disclosed
CN-110938104-B Cyclic dinucleotide analogue, pharmaceutical composition and application thereof 上海迪诺医药科技有限公司 2024-07-12 CN disclosed
EP-0961775-A2 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN Pharmaceuticals, Inc. (US) 1999-12-08 EP disclosed
EP-0636372-B1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives ICN PHARMACEUTICALS (US) 1998-12-02 EP disclosed
WO-1998016184-A2 PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF ICN PHARMACEUTICALS, INC. (US) 1998-04-23 WO disclosed
EP-0348446-B1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES UNIV BRIGHAM YOUNG (US) 1995-08-09 EP disclosed
EP-0636372-A1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives BRIGHAM YOUNG UNIVERSITY (US) 1995-02-01 EP disclosed
EP-0348446-A4 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES 1991-09-25 EP disclosed
US-5041426-A Viricides, antitumor agents BRIGHAM YOUNG UNIVERSITY (US) 1991-08-20 US disclosed
EP-0348446-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES. UNIV BRIGHAM YOUNG (US) 1990-01-03 EP disclosed
US-4880784-A ANTITUMOR AGENTS BRIGHAM YOUNG UNIVERSITY (US) 1989-11-14 US disclosed
WO-1989005649-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES BRIGHAM YOUNG UNIVERSITY (US) 1989-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152051-B2 Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application STING1, CGAS, IRF3 RPS6KA3 3151/4885MAPT 4699/4885DYRK1A 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.